ArticleBlood advances2023

Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.

Camille Rasmussen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.